Essenlix and Roche Diagnostics collaborate to boost at-home testing
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Essenlix and Roche Diagnostics collaborate to boost at-home testing

21 May 2021 (Last Updated May 21st, 2021 12:41)

Essenlix and Roche Diagnostics Norway collaborate to deploy the iMOST platform to increase patient at-home testing.

Essenlix and Roche Diagnostics collaborate to boost at-home testing
iMOST is a rapid, mobile phone-based health test platform that can be used in personal, point-of-care and clinical settings. Credit: Essenlix.

Digital health start-up Essenlix has collaborated with Roche Diagnostics Norway to deploy its instant Mobile Self Test (iMOST) platform to increase patient at-home testing.

Essenlix was selected by Roche as its partner for this initiative after a long association, the company said. Roche will now deploy Essenlix’s iMOST as the platform for its patient-at-home-test solution in the country.

A rapid, portable, mobile phone-connected health test platform, iMOST can be used in personal, point-of-care and clinical settings.

Users can carry out a precise diagnostic health test on themselves, irrespective of the place or time, with one drop of body fluid and a smartphone. The affordable test delivers results within 60 seconds, which will be shared with medical specialists instantly.

Compared to standard instruments and devices, iMOST is different in various aspects.

iMOST is ‘intelligent fault tolerant’ and offers reliable lab-quality test results with the help of a simple device even when sample, device, process and operation are not in ideal conditions.

The ‘all-in-one’ platform utilises a single instrument/device to conduct the test for almost all sample types, including blood, saliva, urine, swaps, sputum, breath, mucus and tissues; as well as for most assay types. It does not require separate specimen holders and instruments.

Essenlix co-founder and chairman Dr Stephen Chou said: “This partnership is an excellent vehicle to further demonstrate and test the capabilities of Essenlix iMOST platform for personal, point-of-care and clinical use in Norway.

“It is also an important step forward to make the iMOST platform a solution to the unmet need of instant personal health testing, providing a key missing link between personal health, remote monitoring and treatment, and e-health services in Norway.”

Essenlix is equipped to produce more than ten million iMOST test cards a year using its manufacturing lines.

Last week, the US Food and Drug Administration granted emergency use authorisation to Roche’s cobas SARS-CoV-2 Test for asymptomatic people and those with suspected Covid-19.